What Eisai Korea does

Eisai Korea Inc. (한국에자이주식회사) is a South Korean pharmaceutical company and wholly-owned Korean subsidiary of the Japanese specialty pharma group Eisai Co., Ltd. (TSE: 4523). Founded in 1997 and headquartered in Gangnam-gu, Seoul, the company markets and distributes a portfolio of specialty prescription drugs across six therapeutic areas: dementia and Alzheimer's disease (Aricept, Ezatin, Leqembi), Parkinson's disease (Equfina), epilepsy (Fycompa, Excegran, Inovelon), multiple sclerosis (Tecfidera, Avonex, Tysabri, Plegridy), oncology (Lenvima, Halaven), gastrointestinal disorders (Pariet), immune diseases (Gisleca), and oral/ocular dryness (Salagen). The company operates an enterprise field sales model via medical representatives and a KGSP-certified logistics center in Hwaseong, distributing products through hospitals, pharmacies, and welfare institutions across Korea.

Eisai Korea runs a dual business model: a pharmaceutical distribution core anchored to high-value parent-company assets, and a parallel digital health ecosystem operated under the Healthcare Ecosystem Mission (HEM). The digital portfolio centers on HeLpy, a family health management app integrated with the National Health Insurance Service and Samsung Health; CogMate, a digital brain health self-testing tool based on the FDA-approved Cogstate Brief Battery that produces Brain Performance Index scores and brain age; and Seomitok/Sema, KakaoTalk chatbot-based cognitive training services across six domains. The company operates the hhc (human health care) corporate philosophy, dedicating 1% of employee working hours to direct patient engagement.

The go-to-market combines medical detailing to healthcare professionals, digital platforms reaching consumers (HeLpy ~800,000 users), and an extensive open-innovation ecosystem of 100+ partners including startups (Neuroexti, Bwave, MindHub, Mago, Cflat), insurance companies (Kyobo Life, Hanwha Life, Heungkuk Fire & Marine), welfare associations, and academic institutions. Strategic partnerships are coordinated through living lab programs (D-Lab, Epil-Lab), the annual Healthcare Ecosystem Symposium, and corporate social innovation initiatives targeting dementia prevention and senior care.

Name

Eisai Korea

Legal name

한국에자이주식회사

Website

https://eisaikorea.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

11–50 employees

Short description

Eisai Korea is a wholly-owned Korean subsidiary of Eisai Co., Ltd. (Japan) that distributes specialty prescription drugs across dementia, Parkinson's, epilepsy, multiple sclerosis, oncology, GI, and immunology, while running a digital health ecosystem (HeLpy, CogMate, Seomitok) through 100+ partnerships with startups, insurers, and welfare organizations.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Psychiatry & Medication Management Platforms (HLALAEAB)

Keywords

• Specialty pharmaceuticals
• Neurological disorder treatments
• Dementia care solutions
• Digital cognitive health
• Pharmaceutical distribution

Headquarters

HQ city

Sunae

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Eisai Korea generates revenue primarily through the sale of prescription pharmaceutical products across multiple therapeutic areas including dementia, Parkinson's disease, epilepsy, multiple sclerosis, oncology, gastrointestinal disorders, and immune diseases. Products are sold to hospitals, pharmacies, and healthcare providers through medical representatives.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Eisai Korea sells a specialty pharmaceutical portfolio covering neurology (dementia, Parkinson's epilepsy, multiple sclerosis), oncology, gastrointestinal disorders, and immune diseases, plus digital health solutions including the CogMate brain health assessment tool, HeLpy family health management app, and Seomitok/Sema cognitive training chatbots. Products are distributed to hospitals, pharmacies, senior welfare centers, and insurance companies across South Korea through medical representatives and partnership channels.

Product overview

Eisai Korea offers a dual portfolio spanning specialty pharmaceuticals across six therapeutic areas (dementia/Alzheimer's, Parkinson's disease, epilepsy, multiple sclerosis, oncology, gastrointestinal disorders, immune diseases, oral/ocular dryness) and a digital health solutions ecosystem. The pharmaceutical portfolio includes core brands such as Aricept (donepezil), Leqembi (lecanemab), Equfina (safinamide), Fycompa (perampanel), Inovelon (rufinamide), Tecfidera (dimethyl fumarate), Avonex (interferon beta-1a), Tysabri (natalizumab), Lenvima (lenvatinib), Halaven (eribulin), Pariet (rabeprazole), Gisleca (filgotinib), and Salagen (pilocarpine). The digital health portfolio centers on three platforms: HeLpy (family health management app with medical record sync and chronic disease tracking), CogMate (FDA-based digital cognitive assessment tool providing BPI scores and brain age measurement), and Seomitok/Sema (AI chatbot-based cognitive training services for dementia prevention). These digital solutions are distributed through the company's Healthcare Ecosystem Mission (HEM) platform, open innovation partnerships with Korean startups, and the Brain Health School (뇌건강학교) community program.

Differentiator

Problem solved

Functional benefit

Products and services

• HeLpy (헬피) Family health management mobile application offering child vaccination reminders, prescription photo registration, medication schedule alerts, multi-year health checkup data viewing via national health insurance integration, chronic disease tracking (blood pressure, blood glucose, diet, sleep, weight), and gamified health quests. Synced with Samsung Health and Korea's National Health Insurance Service.
• CogMate (코그메이트) FDA-approved digital brain health self-testing tool based on the Cogstate Brief Battery (CBB). Measures cognitive performance across 4 domains (brain reaction speed, attention, visual learning, memory) in approximately 15 minutes via PC, smartphone, or tablet. Generates BPI (Brain Performance Index), brain age score, grades, and periodic progress tracking reports.
• Seomitok (새미톡) KakaoTalk chatbot-based cognitive training service offering 6 cognitive domains (calculation, language, concentration, memory, execution, visuospatial) with 23 training games, plus daily conversation-based dementia prevention content. Targets active seniors and elderly users via a familiar mobile messaging platform.
• Pangyo IT Da (판교를 IT다) Regional cognitive health platform and brain training center established at Pangyo General Social Welfare Center, offering IT-based cognitive training programs, VR exercise, AI training robots, cognitive strengthening special zones, and an open lounge community hub. Functions as a regional proof-of-concept center for digital dementia solutions.
• Epil-Lab (에필랩) Epilepsy living lab program (Epilepsy + Living Lab) where epilepsy patients and families identify real-world problems and co-develop solutions with researchers and industry. Season 1 ran in Jeju, Seoul, Daegu, Changwon, and Chilgok developing outputs such as school life guides, awareness videos, web information portals, and caregiver training materials.
• Leqembi IV Injection (레켐비주) Lecanemab 200mg/2mL and 500mg/5mL IV injection for treatment of mild cognitive impairment or mild Alzheimer's disease in adults, administered as 10mg/kg infusions every two weeks. First amyloid-targeting Alzheimer's disease therapy approved in Korea.
• Aricept (아리셉트) Donepezil hydrochloride tablets (5mg, 10mg, 23mg) and orally disintegrating film (5mg, 10mg) for symptomatic treatment of mild to moderate Alzheimer's dementia.
• Ezatin Tablets (에자틴정) Memantine hydrochloride 10mg tablets for treatment of moderate to severe Alzheimer's disease, administered via a stepwise dose escalation starting at 5mg up to a maintenance dose of 20mg daily.
• Equfina Film-Coated Tablets (에퀴나정) Safinamide methanesulfonate 50mg film-coated tablets as adjunctive therapy to levodopa for treatment of idiopathic Parkinson's disease in patients experiencing end-of-dose motor fluctuations.
• Fycompa (파이콤파) Perampanel film-coated tablets (2mg, 4mg, 6mg, 8mg, 10mg, 12mg) and oral suspension (0.5mg/mL) for adjunctive treatment of partial-onset seizures and primary generalized tonic-clonic seizures in epilepsy patients (aged 4+ for partial seizures, 7+ for generalized seizures).
• Excegran Tablets (엑세그란정) Zonisamide 100mg tablets for adjunctive treatment of partial seizures and generalized seizures including partial seizures (including Jacksonian, complex partial, secondarily generalized tonic-clonic), generalized tonic-clonic seizures, and mixed seizure types.
• Inovelon Film-Coated Tablets (이노베론필름코팅정) Rufinamide 200mg and 400mg film-coated tablets as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients aged 1 year and older.
• Tecfidera Capsules (텍피데라캡슐) Dimethyl fumarate 120mg and 240mg enteric-coated capsules for treatment of relapsing forms of multiple sclerosis including relapsing-remitting MS in patients aged 13 years and older, administered as starting dose of 120mg twice daily escalating to maintenance dose of 240mg twice daily.
• Avonex Pen (아보넥스펜주) Interferon beta-1a 30mcg prefilled pen for treatment of relapsing forms of multiple sclerosis, administered as once-weekly intramuscular injection with optional dose titration for flu-like symptom management.
• Tysabri Injection (티사브리주) Natalizumab 300mg IV infusion for monotherapy of highly active relapsing-remitting multiple sclerosis in adult patients who have failed to respond to at least one disease-modifying therapy, and for rapidly evolving severe relapsing-remitting MS. Administered as 300mg every 4 weeks.
• Plegridy Pen (플레그리디펜주) Peginterferon beta-1a 125mcg prefilled pen for treatment of relapsing multiple sclerosis, self-administered as subcutaneous injection every 2 weeks (14 days) with a starter pack containing 63mcg and 94mcg doses for initial dose titration.
• Lenvima Capsules (렌비마캡슐) Lenvatinib mesylate 4mg and 10mg capsules for treatment of radioiodine-refractory progressive differentiated thyroid cancer, unresectable hepatocellular carcinoma as first-line therapy, MSI-H/dMMR advanced endometrial cancer (in combination with pembrolizumab), and renal cell carcinoma (in combination with pembrolizumab).
• Halaven Injection (할라벤주) Eribulin mesylate 0.5mg/mL IV injection for treatment of locally advanced or metastatic breast cancer in patients who have received at least two prior chemotherapy regimens (including anthracycline and taxane), and for unresectable or metastatic liposarcoma in patients who have received prior anthracycline-based chemotherapy.
• Pariet Tablets (파리에트정) Rabeprazole sodium 5mg, 10mg, and 20mg film-coated tablets and enteric-coated tablets for treatment of gastric ulcers, duodenal ulcers, erosive/ulcerative GERD, symptomatic GERD relief, long-term GERD maintenance, H. pylori eradication (in combination with antibiotics), and Zollinger-Ellison syndrome.
• Gisleca Tablets (지셀레카정) Filgotinib 100mg and 200mg film-coated tablets for treatment of moderate to severe active rheumatoid arthritis in adults who have not responded adequately to at least one DMARD, and for moderate to severe active ulcerative colitis.
• Salagen Film-Coated Tablets (살라겐정) Pilocarpine hydrochloride 5mg film-coated tablets for treatment of xerostomia (dry mouth) caused by radiation therapy for head and neck cancer, and for xerostomia and xerophthalmia in Sjogren's syndrome patients.

Quantifiable outcome

• Brain age reduced from 82.6 to 81.8 years in Brain Health School participants
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature3 records

Partnerships

48 partnerships are on record, tiered core and minor.

• Hansalim Seoul Social Cooperative (한살림서울돌봄사회적협동조합)coreStrategic or Co-development Partner · 21 November 2025Dementia patient job creation model development project under Social Economy SE Bridge program, targeting early-stage dementia and MCI patients.
• Neuroexti (뉴로엑스티)coreTechnology or Integration · 6 November 2025AI-based early Alzheimer's diagnosis solution using health examination data to identify high-risk amyloid-positive groups for early screening.
• Bwave (비웨이브)coreTechnology or Integration · 6 November 2025Bio-signal based AI cognitive function evaluation solution 'Maumgeol Basic' that verifies early detection of mild cognitive impairment.
• MindHub (마인드허브)coreTechnology or Integration · 6 November 2025AI cognitive training platform 'GeniCog' supporting early detection of mild cognitive impairment and cognitive function improvement.
• Mago (마고)coreTechnology or Integration · 6 November 2025Voice AI-based conversational platform 'CiniMate' for evaluating cognitive function and emotional state through daily conversation.
• Cflat (씨플랫)coreTechnology or Integration · 6 November 2025AI-based customized conversation service for managing senior emotional and cognitive functions through digital companion platform.
• Kakao MobilitycoreStrategic or Co-development Partner · 6 November 2025Smart mobility technology for elderly driver safety and mobility rights guarantee.
• Kyobo Life Insurance (교보라이프플래닛)coreStrategic or Co-development Partner · 6 November 2025Integration of CogMate and AlzwIN in cognitive function and dementia insurance correlation analysis.
• Resol (리솔)coreTechnology or Integration · 6 November 2025Sleep improvement clinical and wellness device development based on insomnia patient brainwave data.
• Seven Point One (세븐포인트원)coreTechnology or Integration · 6 November 2025Language fluency-based early dementia diagnosis solution 'AlzWin' and cognitive improvement VR solution 'SENTENTS'.
• Medipal (메디팔)coreTechnology or Integration · 6 November 2025Non-face-to-face customized health management solution connecting chronic disease patients with nurse coaches 1:1.
• AHA Consulting (아하컨설팅)coreTechnology or Integration · 6 November 2025Customized dementia prevention and fall prevention AHA mat and system solution.
• Dementia Living Lab Network (돌봄리빙랩네트워크)coreStrategic or Co-development Partner · 24 June 2025Coordinator institution for care living lab network including D-LAB, Epil-LAB, and Bucheon Dementia Care Living Lab.
• Gijang-gun Dementia Center (기장군보건소 치매안심센터)coreStrategic or Co-development Partner · 14 April 2025Garden therapy program for dementia symptom relief, developed with D-Lab dementia living lab and local community partners.
• LeeLeeJang (이이장)minorStrategic or Co-development Partner · 14 April 2025Garden therapy program development partner for dementia care.
• SK TelecomcoreStrategic or Co-development Partner · 18 September 2024AI call-based dementia risk identification and brain health solution promotion targeting 10,000 elderly.
• Solitary Senior Support Center (독거노인종합지원센터)coreStrategic or Co-development Partner · 18 September 2024Dementia prevention through AI-based screening and follow-up care coordination.
• Korean Brain Epilepsy Association (한국뇌전증협회)minorStrategic or Co-development Partner · 18 September 2024Epilepsy awareness and support activities.
• Korea Science and Technology Policy InstituteminorStrategic or Co-development Partner · 18 September 2024Living lab methodology education and support.
• Korean Dementia Society (대한치매학회)coreStrategic or Co-development Partner · 5 September 2024JOY-ALZ registry program for long-term Alzheimer's tracking, treatment environment optimization, and Leqembi safety monitoring.
• Myheart is Bean Pond Cooperative (내마음은콩밭 협동조합)coreStrategic or Co-development Partner · 8 April 2024Epil-LAB living lab for epilepsy patient-centered problem identification and solution development.
• SK TelecomcoreStrategic or Co-development Partner · 31 January 2024AI-based dementia awareness improvement and prevention pilot project using AI calls to reach elderly high-risk groups.
• Solitary Senior Support Center (독거노인종합지원센터)coreStrategic or Co-development Partner · 31 January 2024AI-based dementia awareness campaign targeting isolated seniors through CogMate brain health assessments.
• Sam Chun Dang Pharm (삼천당제약)coreStrategic or Co-development Partner · 28 December 2023HeLpy app integration for diabetes patient health data sharing with medical institutions.
• Korean Senior Welfare Centers Association (한국노인종합복지관협회)coreStrategic or Co-development Partner · 23 March 2023Brain Health School program for senior cognitive health at 20 welfare centers.
• KMI Korean Medical Research Institute (KMI 한국의학연구소)coreStrategic or Co-development Partner · 20 January 2023Dementia prevention and early diagnosis ecosystem building with CogMate introduction at health screening centers.
• Korean Senior Welfare Centers Association (한국노인종합복지관협회)coreStrategic or Co-development Partner · 24 November 2022Eisai Brain Health School operation for senior cognitive wellness at welfare centers.
• Sangsangnanam (마포희망나눔)coreStrategic or Co-development Partner · 27 September 2022Seongmyeongsan Village Care Living Lab for community-based care model development.
• Yonsei University Kim Moum Nursing Research Institute (연세대 김모임간호학연구소)coreStrategic or Co-development Partner · 27 September 2022Community care living lab with nursing education and research partnership.
• Seongnam Senior Industry Innovation Center (성남 시니어산업혁신센터)coreStrategic or Co-development Partner · 27 September 2022Korean Senior Living Lab activation and senior industry development through multi-stakeholder MOU.
• Korea Living Lab Network (한국리빙랩네트워크)coreStrategic or Co-development Partner · 27 September 2022Living lab network coordination and methodology sharing.
• Lotte Duty Free (롯데면세점)minorStrategic or Co-development Partner · 21 June 2022HeLpy health app partnership for homecare customer segment.
• Seongnam Senior Industry Innovation Center (성남 시니어산업혁신센터)coreStrategic or Co-development Partner · 26 April 2022Senior industry innovation through Korean Senior Living Lab activation MOU.
• Jinan-gun (진안군)minorStrategic or Co-development Partner · 13 April 2022Health management content exchange using HeLpy app at Jeonbuk Environmental Disease Healing Center.
• Pangyo Comprehensive Social Welfare Center (판교종합사회복지관)coreStrategic or Co-development Partner · 12 April 2022Pangyo IT Da brain health platform cafe for senior cognitive health.
• Chamsarang (사단법인 참사람들)coreStrategic or Co-development Partner · 12 April 2022IT community care center for healthy life design and cognitive health promotion.
• ItMalp (잇마플)coreStrategic or Co-development Partner · 21 December 2021Low-iodine diet development for thyroid cancer patients undergoing radioactive iodine treatment.
• Daeo (대교)coreStrategic or Co-development Partner · 26 October 2021Cognitive training and dementia prevention program supply cooperation.
• Hai (하이)coreTechnology or Integration · 2 September 2021Digital dementia prevention chatbot 'Sumi' and platform development.
• Eisai-On (에자이-온)coreTechnology or Integration · 2 September 2021Online medical information site for healthcare professionals with e-Library, Medical Affairs, and remote detailing.
• DuChem Bio (듀켐바이오)coreTechnology or Integration · 28 May 2021Dementia diagnosis-treatment healthcare ecosystem building with radiopharmaceutical diagnostics.
• LuxyD Labs (룩시드랩스)coreTechnology or Integration · 28 April 2021VR-based cognitive function improvement solution development and supply.
• Chung-Ang University (중앙대학교)coreStrategic or Co-development Partner · 22 April 2021Brain healthcare device development through academic-industry partnership.
• Hanwha Life Insurance (한화생명)coreStrategic or Co-development Partner · 25 November 2020Digital healthcare platform for senior life ecosystem care with Dreamplus partnership.
• Korean Dementia Society (대한치매학회)coreStrategic or Co-development Partner · 22 October 2020COVID-19 response project for dementia patients with educational materials development.
• Hai (하이)coreTechnology or Integration · 6 July 2020Dementia early detection and prevention platform development using AI technology.
• HeLpy (헬피)coreTechnology or Integration · 16 January 2020Family health management app with vaccination reminders, growth tracking, medication management, and health check integration.
• Korea Blood Cancer Children Foundation (한국백혈병어린이재단)minorStrategic or Co-development Partner · 1 March 2019Monthly donation of 10 million KRW for pediatric cancer patient treatment support, totaling 500 million KRW over 6 years.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Novartis Korea: Korean subsidiary of Novartis, a global pharmaceutical innovator with overlapping CNS and multiple sclerosis franchises (Kesimpta, Mayzent, Gilenya) and digital health partnerships through its innovation programs — closely comparable as a multinational pharma subsidiary operating specialty CNS in Korea with a similar GTM model.
• Dong-A ST: Korean-domestic specialty pharmaceutical company with a neurology and CNS-adjacent franchise (Stillen, Motilitone) and growing digital health exposure — comparable as a Korea-headquartered pharma player competing in overlapping CNS categories with a similar go-to-market via medical representatives.
• AstraZeneca Korea: Korean subsidiary of AstraZeneca operating oncology plus specialty pharma with strong digital health and ecosystem programs (including partnerships with Korean tech players) — comparable as a multinational pharma subsidiary executing parallel digital health ecosystem strategy alongside pharma commercialization.
• Hanmi Pharmaceutical: Korea's largest domestic pharmaceutical company with specialty pharma franchises across oncology, immunology, and CNS-adjacent areas — a comparable Korea-based pharma competitor operating in overlapping specialty therapeutic categories through similar medical-rep-driven GTM.
• Lundbeck Korea: Danish-headquartered specialty pharma with a concentrated CNS focus (depression, schizophrenia, Alzheimer's, Parkinson's) operating in Korea — the closest direct CNS specialty peer to Eisai Korea's neurology franchise depth and disease-area emphasis on dementia.
• Bayer Korea: Korean subsidiary of Bayer, operating pharma plus consumer health with digital health initiatives — comparable multinational pharma subsidiary structure with a similar mix of established prescription drugs and growing digital health ecosystem in Korea.
• Sanofi Korea: Korean subsidiary of Sanofi operating specialty pharma (Dupixent, neurology, rare disease) with active digital health and ecosystem partnerships — comparable multinational pharma subsidiary structure with innovation and patient ecosystem programs analogous to Eisai Korea's HEM.
• Pfizer Korea: Korean subsidiary of Pfizer with a broad specialty pharma portfolio and active local ecosystem/innovation partnerships — a directly comparable multinational pharma subsidiary in scale, GTM model, and breadth of therapeutic area coverage in Korea.
• Roche Korea: Korean subsidiary of Roche, with strong neurology/oncology franchises (Ocrevus for MS, oncology portfolio) and digital diagnostics partnerships — a comparable specialty pharma subsidiary operating a similar CNS-plus-oncology mix with innovation-led GTM in Korea.

Emerging players

• Kakao Healthcare: Korea-based digital health platform built on Kakao's consumer reach, pursuing AI-driven personal health management and chronic disease tools — a meaningful adjacent digital health peer to Eisai Korea's HeLpy/CogMate ecosystem, particularly given KakaoTalk is also the delivery channel for Eisai Korea's Sumi Talk cognitive training chatbot.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eisai Korea